What is the price of Apelix?

Apelix is an innovative drug targeting specific types of breast cancer. It is especially suitable for patients with hormone receptor-positive, human epidermal growth factor receptor2-negative, and advanced or metastatic breast cancer patients who carry PIK3CA gene mutations. Such patients often face the dilemma of limited treatment options, and the emergence of Apelvis brings new treatment hope to these patients.

The main mechanism of action of Apelvis is to prevent the growth and spread of cancer cells by inhibiting the activity of thePI3K signaling pathway. The drug can precisely act on cancer cells carrying PIK3CA mutations, causing relatively little harm to normal cells, and therefore has relatively few side effects. In clinical trials, progression-free survival was significantly prolonged in patients treated with apelisib combined with fulvestrant, further supporting the effectiveness of apeliside in the treatment of this type of breast cancer.

In addition, the use of Apelvis may also be associated with some side effects, such as hyperglycemia, increased creatinine levels, diarrhea, etc. Therefore, it is necessary to pay close attention to the patient's symptom changes during use and adjust the treatment plan in a timely manner.

Currently, Apelvis has not yet been launched in China. Therefore, patients in need can only purchase it through overseas channels or contact professional overseas medical consulting companies. It is reported that Apelvis has been launched in Hong Kong, my country. The original drug is produced by Swiss Novartis Pharmaceuticals in 150mg*56 capsules. Each box is priced at 41,000 yuan. Although the price of Apelvis in Hong Kong is on the high side, we found that the price of the original drug of the same specifications in the Indian market is only 5,080 yuan, while the price of Lucius in Laos is as low as about 2,500 yuan. For more information about Apelvis, please consult a regular overseas medical consulting company.

Overall, Apelvis provides a new treatment option for patients with specific types of breast cancer, and its unique mechanism makes treatment more targeted and effective. Although the drug has not yet been launched in mainland China, its clinical performance in other countries and regions has attracted widespread attention, and it is expected that it will bring good news to more patients in the future.